2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting.
Christina Halgaard Bruvik RuhlmannKarin JordanFranziska JahnErnesto MaranzanoAlex MolassiotisKristopher DennisPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2023)
As for the previous guideline, the serotonin receptor antagonists are still the cornerstone in antiemetic prophylaxis of nausea and vomiting induced by high and moderate emetic risk radiotherapy. The guideline update provides new recommendation for the management of C-RINV for radiotherapy and concomitant weekly cisplatin. To avoid overtreatment, antiemetic prophylaxis is no longer recommended for the "low emetic risk" category.